158 related articles for article (PubMed ID: 37848676)
1. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy.
Kreps EO; Epps SJ; Consejo A; Dick AD; Guly CM; Ramanan AV
Eye (Lond); 2024 Apr; 38(5):871-876. PubMed ID: 37848676
[TBL] [Abstract][Full Text] [Related]
2. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
3. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of the infliximab biosimilar (CT-P13) in paediatric patients with non-infectious uveitis.
Sözeri B; Kardeş E; Salı E; Çakır D; Demir F
Clin Exp Rheumatol; 2021; 39(4):907-912. PubMed ID: 33635217
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
[TBL] [Abstract][Full Text] [Related]
6. Changing biological disease modifying treatment for paediatric uveitis in the real world.
Oh LJ; Nguyen CL; Phan K; Wong E; Zagora S; Singh-Grewal D; Chaitow J; Grigg JR; McCluskey P
Clin Exp Ophthalmol; 2019 Aug; 47(6):741-748. PubMed ID: 30834650
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis.
Ashkenazy N; Saboo US; Abraham A; Ronconi C; Cao JH
J AAPOS; 2019 Jun; 23(3):151.e1-151.e5. PubMed ID: 31063811
[TBL] [Abstract][Full Text] [Related]
8. Long-term Experience with Anti-tumor Necrosis factor- α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis.
Corredores Dieb J; Vofo B; Amer R
Ocul Immunol Inflamm; 2022 Dec; ():1-8. PubMed ID: 36538811
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and tolerability of TNFα inhibitors in the treatment of non-infectious ocular inflammation: an 8-year prospective surveillance study.
Sharma SM; Damato E; Hinchcliffe AE; Andrews CD; Myint K; Lee R; Dick AD
Br J Ophthalmol; 2021 Sep; 105(9):1256-1262. PubMed ID: 30862619
[TBL] [Abstract][Full Text] [Related]
10. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: Infliximab Versus Adalimumab.
Ucan Gunduz G; Yalcinbayir O; Cekic S; Yildiz M; Kilic SS
J Ocul Pharmacol Ther; 2021 May; 37(4):236-240. PubMed ID: 33512278
[No Abstract] [Full Text] [Related]
11. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
[TBL] [Abstract][Full Text] [Related]
12. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis.
Miraldi Utz V; Bulas S; Lopper S; Fenchel M; Sa T; Mehta M; Ash D; Lovell DJ; Kaufman AH
Pediatr Rheumatol Online J; 2019 Nov; 17(1):79. PubMed ID: 31783768
[TBL] [Abstract][Full Text] [Related]
14. Biological therapy in refractory cases of uveitis and scleritis: An analysis of 18 cases from a tertiary eye care center from South India.
Sadhu S; Dutta Majumder P; Biswas J
Indian J Ophthalmol; 2020 Sep; 68(9):1929-1933. PubMed ID: 32823417
[TBL] [Abstract][Full Text] [Related]
15. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
16. Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis.
Simonini G; Taddio A; Cattalini M; Caputo R; de Libero C; Parentin F; Pagnini I; Lepore L; Cimaz R
Pediatr Rheumatol Online J; 2013; 11():16. PubMed ID: 23587261
[TBL] [Abstract][Full Text] [Related]
17. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.
Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV
Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory therapy with tumour necrosis factor α inhibitors in children with antinuclear antibody-associated chronic anterior uveitis: long-term results.
Doycheva D; Zierhut M; Blumenstock G; Stuebiger N; Januschowski K; Voykov B; Deuter C
Br J Ophthalmol; 2014 Apr; 98(4):523-8. PubMed ID: 24457365
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.
Mercier AE; Ribeiro E; Korobelnik JF; Delyfer MN; Rougier MB
Ocul Immunol Inflamm; 2018; 26(3):477-484. PubMed ID: 27775458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
